SCHEMBL6408591

SCHEMBL6408591

CC1c2ccccc2CCN1c1ncc[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.46
ADRA2A P08913 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1B P35368 1/20 0.44
DRD1 P21728 1/20 0.36
PRCP P42785 2/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
MAPT P10636 2/20 0.35
RGS12 O14924 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
KMT2A Q03164 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8805271 0.77 PRCP (0.40) ADRA1AADRA2ADRD1PRCPTRPM8
SCHEMBL2600445 0.72 PRCP (0.47) DRD1PRCPTRPM8CHRNA7
SCHEMBL25163043 0.72 PRCP (0.47) DRD1PRCPTRPM8CHRNA7
SCHEMBL23112103 0.72 AKR1C3 (0.39) ADRA1AADRA2ADRD1PRCPTRPM8
SCHEMBL23112118 0.70 ROCK1 (0.37) ADRA1AADRA2ADRD1PRCPTRPM8
SCHEMBL6994246 0.70 DRD1 (0.40) DRD1PRCPTRPM8KDM4EGRM5
SCHEMBL5319075 0.69 ROCK1 (0.50) ADRA1AMAPTMEN1KMT2A
SCHEMBL8803439 0.69 DRD1 (0.39) ADRA1AADRA1DADRA1BDRD1PRCP
SCHEMBL1735608 0.68 MAPT (0.37) ADRA1AADRA2AADRA1DADRA1BDRD1
SCHEMBL28848016 0.68 ALDH1A1 (0.45) DRD1PRCPTRPM8MAPTCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849644-B2 Isoquinoline derivatives useful in the treatment of CNS disorders SMITHKLINE BEECHAM P.L.C. (GB) 2005-02-01 US disclosed
US-20040053956-A1 Isoquinoline derivatives useful in the treatment of cns disorders SMITHKLINE BEECHAM P.L.C. (GB) 2004-03-18 US disclosed
EP-1341783-A1 ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM PLC (GB) 2003-09-10 EP disclosed
WO-2002042293-A1 ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053956-A1 Isoquinoline derivatives useful in the treatment of cns disorders INA, NLN, GRIN2C ADRA1A 640/4885ADRA2A 356/4885ADRA1D 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.